{"id":53762,"date":"2025-05-07T16:15:00","date_gmt":"2025-05-07T14:15:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/report-from-stilles-annual-general-meeting-2025\/"},"modified":"2025-05-07T16:15:00","modified_gmt":"2025-05-07T14:15:00","slug":"report-from-stilles-annual-general-meeting-2025","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/report-from-stilles-annual-general-meeting-2025\/","title":{"rendered":"Report from Stille\u2019s Annual General Meeting 2025"},"content":{"rendered":"
\n

The 2025 annual general meeting in Stille AB was held on Wednesday, May 7, 2025, on Norrlandsgatan 11 in Stockholm. The main resolutions passed at the annual general meeting were as follows. More detailed information about the contents of the resolutions may be obtained from the complete notice of the annual general meeting and the complete proposals, which are available on the company\u2019s website.<\/strong><\/p>\n<\/div>\n

\n

Adoption of the income statements and the balance sheets<\/strong><\/p>\n

The annual general meeting adopted the presented income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet for 2024.<\/p>\n

Disposition of the company\u2019s results<\/strong><\/p>\n

The annual general meeting approved, in accordance with the board\u2019s proposal, that no dividend shall be paid for the financial year 2024.<\/p>\n

Discharge from liability<\/strong><\/p>\n

The annual general meeting resolved to discharge the board members and the CEO from liability for the past year.<\/p>\n

Board and auditors<\/strong><\/p>\n

The annual general meeting resolved, in accordance with the nomination committee\u2019s proposal, that the board shall be composed of five (5) members elected by the meeting, with no alternates, and that the number of auditors shall be one without an alternate.<\/p>\n

The annual general meeting resolved, in accordance with the nomination committee\u2019s proposal, to re-elect Per Carlsson, Yonna Olsson, Victor Steien and Jens Viebke, as well as to elect J\u00f3n Sigurdsson, as board members for the time until the next annual general meeting. The annual general meeting also resolved, in accordance with the nomination committee\u2019s proposal, to elect J\u00f3n Sigurdsson as the new chair of the board. In addition, the annual general meeting also resolved, in accordance with the nomination committee\u2019s proposal, to re-elect the registered accounting firm R\u00e5dek AB as the company\u2019s auditor, with Johan Rudengren as auditor in charge.<\/p>\n

The annual general meeting resolved, in accordance with the nomination committee\u2019s proposal, that the fees to the board shall be SEK 600,000 to the chair of the board and SEK 150,000 to each of the other board members elected by the meeting. The annual general meeting also resolved, in accordance with the nomination committee\u2019s proposal, that fees will be paid to the auditor in accordance with approved invoices.<\/p>\n

Principles for remuneration and other terms of employment for senior executives<\/strong><\/p>\n

The annual general meeting resolved, in accordance with the board\u2019s proposal, to approve the principles for remuneration and other terms of employment for senior executives.<\/p>\n

Issue authorization<\/strong><\/p>\n

The annual general meeting resolved, in accordance with the board\u2019s proposal, to authorize the board to issue new shares. Such share issues may deviate from the shareholder\u2019s preferential rights to subscribe for new shares. The issue of new shares may only increase the total number of shares by 900,000 shares, meaning around 10 % of the total number of shares in the company.<\/p>\n

Warrant program 2025\/2028<\/strong><\/p>\n

The annual general meeting resolved, in accordance with the board's proposal, to adopt a long-term incentive program for the certain members of management in the Stille group, whereby warrants will be issued without payment of any consideration to the company which will thereafter transfer the warrants to the participants for the warrants\u2019 market price. As of March 28, 2025, the value of one warrant amounted to SEK 42.9, which corresponds to the warrant\u2019s preliminary market value with the application of a determined valuation method (Black & Scholes).<\/p>\n

The board deems it to be in the interest of the company and its shareholders that members of management are engaged in the development of the company by being offered to acquire warrants in an incentive program. Such offer is expected to lead to increased motivation and an increased sense of belonging with the company, as well as to an increased interest in the business and performance of the company.<\/p>\n

In total, 100,000 warrants will be issued to enable allotment, which corresponds to approximately 1.1 percent of the company\u2019s outstanding shares. For each warrant, the holder is entitled to subscribe for one new share against cash payment of a subscription price that shall correspond to 125 percent of the volume-weighted average price of the company\u2019s share during a period of five trading days from and including May 23, 2025, up to and including May 30, 2025 however, never less than the quota value of the company\u2019s share. Subscription for shares based upon warrants may take place during a period of one month commencing on the day after the company's quarterly report for Q1 for the financial year 2028 has been made public.<\/p>\n<\/div>\n

\n

Contact Details<\/strong>
The Board of Directors of Stille AB<\/strong>
Ekbacken 11, SE-644 30 Torsh\u00e4lla
+46 (0)8 588 580 00 | www.stille.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Stille AB (publ) develops, manufactures and markets medical devices<\/strong> for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se<\/a>.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Report from Stille\u2019s Annual General Meeting 2025<\/a><\/p>\n<\/div>\n